1,1-dimethyl-7-acetyl-tetralin | 53326-65-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 1,1-dimethyl-7-acetyl-tetralin
• 英文别名: methyl [8,8-dimethyl (5,6,7,8-tetrahydronaphthalen)-2-yl] ketone；1-(8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-ethanone；2-acetyl-8,8-dimethyl-5,6,7,8-tetrahydronaphthalene；1-(8,8-dimethyl-6,7-dihydro-5H-naphthalen-2-yl)ethanone
• CAS: 53326-65-1
• 化学式: C₁₄H₁₈O
• 分子量: 202.296
• InChiKey: YXIIZVXPGZQGQP-UHFFFAOYSA-N

物化性质

• 沸点：
  314.0±31.0 °C(Predicted)
• 密度：
  0.981±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,1-dimethyl-7-acetyl-tetralin 、 ethyl 4-(diethoxyphosphorylmethyl)benzoate 在 dimsylsodium 、 sodium ethanolate 作用下， 生成 Ethyl 4-<(Z)-2-(1,1-dimethyl-1,2,3,4-tetrahydro-7-naphthyl)-propenyl>benzoate 、 Ethyl 4-<(E)-2-(1,1-dimethyl-1,2,3,4-tetrahydro-7-naphthyl)-propenyl>benzoate
  参考文献：
  名称：

  A method for the stereoselective synthesis of (E)-methylstilbene retinoids

  摘要：

  DOI：

  10.1021/jo00200a055
• 作为产物：
  描述：

  4,4-二甲基-3,4-二氢-2H-萘-1-酮 在 palladium on activated charcoal 盐酸 、 三氯化铝 、 氢气 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 25.0 ℃ 、413.69 kPa 条件下， 反应 8.0h， 生成 1,1-dimethyl-7-acetyl-tetralin
  参考文献：
  名称：

  Protein tyrosine kinase inhibitory properties of planar polycyclics obtained from the marine sponge Xestospongia cf. carbonaria and from total synthesis

  摘要：

  Nine related polycyclic quinones and hydroquinones of the halenaquinone class were isolated from two Indo-Pacific collections of the sponge Xestospongia cf. carbonaria. The halenaquinone family appears not to be of polyketide origin but can be biogenetically derived by the union of a sesquiterpene and a quinone. Four new metabolites were characterized including tetrahydrohalenaquinone B (8a), 14-methoxyhalenaquinone (9), xestoquinolide A (10), and xestoquinolide B (11). These were accompanied by five known compounds, halenaquinone (3), halenaquinol (4), halenaquinol sulfate (5), xestoquinone (6), and tetrahydrohalenaquinone A (7a). The new structures were established from 2D NMR data, and the absolute stereochemistry of the chiral centers in 7 and 8 was determined by the formation of 7b and 7c, the bis esters of O-methylmandelic acid. A series of polycyclic models of natural products 3 and 6 were synthesized and included 16-23. The more complex members of this group were assembled via a 4 + 2 cycloaddition between an o-quinodimethane and a functionalized enone. The marine natural products plus two known fungal metabolites, viridin (13) and wortmannin (14), along with halenaquinone synthetic model compounds, were each tested for their ability to inhibit the activity of pp60v-src protein tyrosine kinase (PTK). Halenaquinone and 14-methoxyhalenaquinone were the most potent with IC50 values <10 muM. The other compounds were either less potent or inactive, and a rationalization for this SAR (structure activity relationship) pattern is presented.

  DOI：

  10.1021/jo00070a023

文献信息

• Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors
  申请人：Tsang Yin Kwok

  公开号：US20050148590A1

  公开（公告）日：2005-07-07

  Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RAR γ agonist retinoids, such as skin related diseases, including but not limited to acne and psoriasis.

  式中变量的定义如规范中所述，对于预防或治疗哺乳动物的肺气肿和相关肺部疾病以及其他对RARγ激动剂类维生素A酸类药物敏感的疾病和病况是有用的，例如皮肤相关疾病，包括但不限于痤疮和牛皮癣。
• INHIBITORS OF SPHINGOSINE KINASE
  申请人：Stieber Frank

  公开号：US20120252815A1

  公开（公告）日：2012-10-04

  The present invention relates to compounds of the formula (I), in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , M 1 , M 2 , M 3 , Y 1 , Y 2 , V, W, n, m and o have the gleanings given herein, and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use in the treatment of diseases which are influenced by inhibition of Sph kinase 1.

  本发明涉及化合物的结构式(I)，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、M1、M2、M3、Y1、Y2、V、W、n、m和o具有此处所述的含义，以及其生理上可接受的盐、衍生物、前药、溶剂化合物、互变异构体和立体异构体，包括所有比例的混合物，用于治疗受Sph激酶1抑制影响的疾病。
• THIAZOLYL PIPERIDINE DERIVATIVES
  申请人：Stieber Frank

  公开号：US20110105505A1

  公开（公告）日：2011-05-05

  Compounds of the formula (I), in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 10 , R 11 , Q and W have the meanings indicated in Claim 1 , and precursors thereof are inhibitors of sphingosine kinase and can be employed, inter alia, for the treatment of tumours.

  式(I)的化合物中，其中R1、R2、R3、R4、R5、R6、R9、R10、R11、Q和W具有权利要求书中所示的含义，以及它们的前体是鞘氨醇激酶的抑制剂，可用于治疗肿瘤等用途。
• Tetralin esters of phenols or benzoic acids having retinoid like activity
  申请人：Allergan, Inc.

  公开号：US05130335A1

  公开（公告）日：1992-07-14

  Retinoid-like activity is exhibited by compounds of the formula ##STR1## where the R groups are independently hydrogen, or lower alkyl; A is --C(O)O--, --OC(O)--, --C(O)S--, or --SC(O)--; n is 0-5; and Z is H, --COB where B is --OH or a pharmaceutically acceptable salt, or B is --OR.sub.1 where R.sub.1 is an ester-forming group, or B is --N(R).sub.2 where R is hydrogen or lower alkyl, or Z is --OE where E is hydrogen or an ether-forming group or --COR.sub.2 where R.sub.2 is hydrogen, lower alkyl, phenyl or lower alkyl phenyl, or Z is --CHO or an acetal derivative thereof, or Z is --COR.sub.3 where R.sub.3 is --(CH.sub.2).sub.m CH.sub.3 where m is 0-4 and the sum of n and m does not exceed 4.

  该公式中化合物展现出类似视黄醇的活性，其中R基可以独立地是氢或较低烷基；A是--C(O)O--，--OC(O)--，--C(O)S--或--SC(O)--；n为0-5；Z是H，--COB，其中B为--OH或药用可接受的盐，或者B为--OR.sub.1，其中R.sub.1是酯形成基团，或者B为--N(R).sub.2，其中R为氢或较低烷基，或Z为--OE，其中E为氢或醚形成基团，或--COR.sub.2，其中R.sub.2为氢、较低烷基、苯基或较低烷基苯基，或者Z为--CHO或其缩醛衍生物，或者Z为--COR.sub.3，其中R.sub.3为--(CH.sub.2).sub.m CH.sub.3，其中m为0-4，且n和m的总和不超过4。
• Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
  申请人：Allergan, Inc.

  公开号：US07476673B2

  公开（公告）日：2009-01-13

  Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RARγ agonist retinoids, such as skin related diseases, including but not limited to acne and psoriasis.

  式子中变量的定义如规范所述，对于预防或治疗哺乳动物的肺气肿和相关肺部疾病以及其他对RARγ激动剂视为响应的疾病和情况，如皮肤相关疾病（包括但不限于痤疮和银屑病）非常有用。